Gene set analysis methods: a systematic comparison

1 Citation

Mathur, R., Rotroff, D., Ma, J., Shojaie, A., & Motsinger-Reif, A. , Gene set analysis methods: a systematic comparison, 2018, BioData mining, 11(1), 8.

Permanent link to the paper

2 Summary

Approaches for gene set analyses were assessed by using simulated data that were generated based on a real experimental data set.

3 Study outcomes

3.1 Outcome O1: False positives under null distribution

The frequency of false-positives was assessed by using an alpha=0.05. Consequently all approaches (except FET-1k) showed around 5% false-positive or less. FET-1k ("FET global statistic in SAFE") had around than 20%.

Outcome O1 is presented as Figure 2 in the original publication for the prostate data template and in the "Additional File 1" for the other templates.

Baseline of this outcome is that all approaches excep FET-1k perform similarly well in terms of false-positives.

3.2 Outcome O2

• sigPathway showed superior performance
• SAFE-Wilcoxon could NOT detect the differentially regulated pathway(s).
• In general, the performance increases with increasing fraction of regulated genes (parameter pi in the paper), except for "Comp GSEA Q" that shows counterintuitive performance.

Outcome O2 is presented as Figure 3 in the original publication, the numbers are provided in the supplement.

3.3 Outcome O3

• SAFE again performs weak for most configurations
• Only "aveDiff-boot" seems to have a good power that improves with increasing magnitudes tau of regulation
• FET-1k, FET-10k could identify the regulated pathway but shows counterintuitive performance (i.e. decreasing performances for increasing magnitudes of regulation)

Outcome O3 is presented as Figure 4 in the original publication.

3.4 Outcome O4

• COMP-GSEA-FDR and Self-GSEA-FDR showed superior performance
• Comp-GSEA-Q and SELF-GSEA-Q showed counterintuitive performance, i.e. the performance deceases with increasing effect size tau

4 Study design and evidence level

4.1 General aspects

• The authors compared four different methods:
  • Gene Set Enrichment Analysis (GSEA)
  • Significance Analysis of Function and Expression (SAFE)
  • sigPathway, and
  • Correlation Adjusted Mean RAnk (CAMERA).
• The authors consider different sizes of the gene sets
• The authors consider different proportions of regulated genes in the gene sets
• The authors consider different magnitudes of the underlying effect size (i.e. log-fold-changes)
• The authors consider three null simulations (without regulation) as reference for outcome O1
• In this publication, the authors published a novel simulation approach termed (FANGS)
• The simulation approach is available in this R package (FANGS) offers the opportunity to reproduce the simulations and repeat the analysis for other gene set methods.
• The authors provide a comprehensive list of the used configuration parameters
• The authors evaluated the following alternative configurations
  • For GSEA one alternative
  • For SAFE five alternative setups
  • For sigPathway and CAMERA no other configurations were considered
• Three experimental data sets were used as foundations for simulating data
  • prostate cancer (264 cases, 160 controls)
  • ischemic stroke (20 cases, 20 controls)
  • normal brain tissue (21 cases, 20 controls)

4.2 Design for Outcome O1

• The authors consider three null simulations (without regulation) as reference:
  • permutation of class labels
  • independently sampled expression of all features (=genes)
  • centering the simulated data, i.e. set effect size to zero
• Default configuration parameters and the alternative parameters described above were evaluated
• Only the prostat cancer data set was considered as template for simulations

4.3 Design for Outcome O2

• The outcome was generated by simulating differential expression of one pathway
• The analysis was repeated for all three data sets as template
• For each of the three data sets the analysis was repeated by selecting two different pathways as differentially regulated.
• In total, six analyses were performed (3 data sets x 2 regulated pathways)
• Default configuration parameters were chosen

4.4 Design for Outcome O3

• The weak performance of SAFE for the default configuration in O2 seems to be the motivation for investigation of other configurations for SAFE
• The outcome O3 was only generated for one data sets (prostate cancer) and two regulated pathways

6 References

The list of cited or related literature is placed here.